

Technology Advisory Committee D Interests Register

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]

Publication Date: 15 December 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	TA Committee Member	Indirect financial	Professor Meads is employed by the University of Leeds which has received funding from Takeda for research in an unrelated area.	N/A	11.06.2020	N/A	It was agreed that this declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Amanda Matse-Orere	TA Committee Member	Financial	Ms Matse-Orere is employed by comparator company Roche.	N/A	17.06.2020	N/A	It was agreed that this declaration would prevent Ms Matse-Orere from participating in discussions on this appraisal.
Dr Matt Bradley	TA Committee Member	Indirect financial	Dr Bradley is employed by GSK, who are in a co-marketing agreement with Kyowa Kirin for medicine in an unrelated disease area which is only available in Japan.	N/A	30.12.2020	N/A	It was agreed that this declaration would not prevent Dr Bradley from participating in discussions on this appraisal.

Dr Ed Wilson	TA Committee Member	Indirect financial	Dr Wilson declared financial interests as Eisai, Pfizer and Takeda are or have been clients of his company in the last three years, but they have not worked on drugs related to this appraisal.	N/A	28.09.2021	N/A	It was agreed that this declaration would not prevent Dr Wilson from participating in discussions on this appraisal.
Dr Eve Gallop-Evans	Clinical expert	Financial	Dr Gallop-Evans received honorarium from Kyowa Kirin for an advisory board meeting on 4 March 2019.	N/A	12.11.2019	N/A	It was agreed that this declaration would not prevent Dr Gallop-Evans from providing expert advice on this appraisal.
Professor Julia Scarisbrick	Clinical expert	Financial	Professor Scarisbrick is PI on the MAVORIC trial 2 and has previously received consultancy fees from Kyowa Kirin and a research grant whilst studying quality of life 2019 at University Hospital Birmingham.	N/A	14.11.2019	N/A	It was agreed that this declaration would not prevent Professor Scarisbrick from providing expert advice on this appraisal.
Steven Scowcroft	Patient expert	Indirect financial	Lymphoma Action is supported by pharma organisations including Kyowa Kirin and has received funding from	N/A	04.06.2020	N/A	It was agreed that this declaration would not prevent Mr Scowcroft from providing expert

			Roche and Takeda in unrelated areas.				advice on this appraisal.
Professor Richard Cowan	Clinical expert	Financial	Professor Cowan has participated in advisory groups and done consultancy work for Kyowa Kirin in the past.	N/A	08.11.2019	N/A	It was agreed that this declaration would not prevent Professor Cowan from providing expert advice to the committee.
Professor Sean Whittaker	Clinical expert	Non-financial	Professor Whittaker has previously been invited to sit on a Kyowa Kirin advisory board.	N/A	05.10.2021	N/A	It was agreed that this declaration would not prevent Professor Whittaker from providing expert advice to the committee.